Total Funding
55
85
Total FundingPost-IPO Debt raised
Growth Score
-14 pts
Heat Score
39 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
11529
Travere discovers and develops drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening.
Acquired by 
Clinuvel Pharmaceuticals
William E. Rote: Senior VP of Research and DevelopmentPast Role: PSYLIN NEUROSCIENCES, COO- Laura Clague: Chief Financial Officer
About the Company
Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring no-cost genetic testing aimed at improving the diagnostic odyssey for children born with cholestasis; partnering with patient advocacy organizations to meet the diverse needs of patients and their families; and ensuring
broad access and education for its FDA-approved therapies.
